Powered by

Gilead Presents New Data from Antiviral Development Programs at IDWeek 2020

Oct 19, 2020 - Business Wire

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of 18 abstracts spanning the company's HIV treatment and prevention and COVID-19 clinical development programs during the virtual IDWeek 2020 conference from October 21-25. The breadth of data reflects Gilead's commitment to advancing antiviral innovation aiming to help end the HIV epidemic and to addressing the treatment needs of patients with COVID-19.

"The global HIV epidemic and the COVID-19 pandemic are two of the m...